Funder: Bill and Melinda Gates Foundation
Due Dates: January 31, 2025 (Option A) | May 31, 2025 (Option B)
Funding Amounts: Option A: Up to $750,000 per project (up to 18 months); Option B: Funding and duration negotiated per project
Summary: Seeks transformative innovations to reduce monoclonal antibody manufacturing costs to $10/gram, expanding global access to life-saving therapies.
Key Information: Applicants must apply through a recognized corporate entity; proposals must focus on manufacturing solutions, not molecule modification or delivery methods.